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Dominantly inherited mutations in an endoplasmic reticulum protein called VAPB have been found 
in a subset of patients with a rare familial form of amyotrophic lateral sclerosis (ALS). In this 
issue, Tsuda et al. (2008) identify a secreted form of VAPB that binds directly to Eph receptors 
inducing their activation and signaling, providing fresh insights into ALS pathogenesis, including 
non-neuronal aspects of this disorder.Amyotrophic lateral sclerosis (ALS) is a 
fatal neurodegenerative disease charac-
terized by a progressive loss of upper and 
lower motor neuron function. Although 
environmental and genetic factors may 
contribute to disease susceptibility, 95% 
of patients do not have an obvious family 
history of ALS (Schymick et al., 2007). A 
prevailing hypothesis is that understand-
ing the mechanisms responsible for the 
relatively rare familial cases may uncover 
targets for therapeutic intervention in 
the more common sporadic forms of the 
disease. Indeed, mutations in a subset 
of familial ALS patients have been identi-
fied in a variety of genes including those 
encoding superoxide dismutase (SOD1, 
accounting for approximately 20% of 
familial ALS) and VAPB, ALS2, DCTN1, 
SETX, and TARDBP (Pasinelli and Brown, 
2006; Sreedharan et al., 2008). The role 
of these mutations in disease pathogen-
esis is under intensive investigation. New 
work in this issue by Tsuda et al. (2008) 
explores the function of the VAMP-as-
sociated membrane protein B (VAPB), 
a protein located in the endoplasmic 
reticulum (ER). They demonstrate that 
VAPB has a secreted form that binds to 
Eph receptors and activates them, and 
that a disease-causing mutation in VAPB 
disrupts secretion of this protein.
A dominantly inherited proline 56 to 
serine (P56S) missense mutation in the 
VAPB gene was first identified in a large 
Brazilian family with a slowly progres-
sive and late-onset atypical form of ALS 
(Nishimura et al., 2004). Interestingly, 
individuals carrying the same mutation have been described with three distinct 
conditions ranging from a late-onset 
slowly progressing form of spinal mus-
cular atrophy (SMA), to an atypical slowly 
progressing form of ALS (ALS8), to a 
typical severe and rapidly progressing 
ALS (Marques et al., 2006; Nishimura et 
al., 2004). Studies characterizing VAPB 
carrying the P56S mutation in cultured 
cells showed that it accumulates in the 
ER and sequesters the wild-type protein 
into ubiquitinated inclusions (Nishimura 
et al., 2004; Teuling et al., 2007). These 
data suggest that the P56S mutation 
acts in a dominant-negative fashion to 
disrupt the normal activity of ER-local-
ized VAPB. Normal functions of VAPB 
may include regulation of vesicle traffick-
ing, ceramide and sphingomyelin trans-
port and synthesis, and maintenance of 
ER homeostasis.
The exciting work of Tsuda et al. (2008) 
identifies a new activity of VAPB that may 
play an important role in the normal func-
tion and maintenance of motor neurons. 
Working in a fly model, these authors show 
that the new activity resides in a secreted 
form of the Drosophila VAPB homolog, 
VAP33A (dVAP), which contains an evo-
lutionarily conserved N-terminal major 
sperm protein (MSP) domain. Analysis of 
human serum demonstrated that like dVAP, 
the MSP domain of VAPB is secreted. The 
dVAP protein with a P58S mutation (cor-
responding to the human P56S mutation) 
is not cleaved or secreted and is retained 
within ER aggregates, suggesting that the 
P56S mutation would disrupt the potential 
activity of secreted VAPB fragments.Cell Using flies overexpressing either 
wild-type or P58S dVAP, Tsuda et al. 
show that secreted dVAP has signal-
ing activity. In previous work, loss of 
dVAP at the neuromuscular junction 
has been shown to result in a decrease 
in the number of synaptic boutons and 
an increase in their size. In contrast, 
overexpression of wild-type dVAP in 
presynaptic neurons increases the 
number of boutons but decreases their 
size, leading to a disruption in flight 
ability (Pennetta et al., 2002). However, 
Tsuda et al. now demonstrate that over-
expression of P58S dVAP in presynap-
tic neurons has no significant effect on 
bouton number or size and only a mild 
impact on flight activity. Interestingly, 
neuronal overexpression of wild-type 
dVAP also induces structural abnor-
malities in flight muscles that were not 
observed in flies expressing mutant 
dVAP. These data suggest that loss of 
dVAP secretion imparted by the P58S 
mutation prevents these overexpres-
sion phenotypes that are at least in 
part mediated by the MSP domain of 
secreted dVAP.
The presence of the MSP domain in 
the VAPB protein suggested that VAPB 
may share signaling functions with the 
MSP sperm-specific proteins, which 
mediate oocyte maturation and ovar-
ian sheath contraction in the worm 
Caenorhabditis elegans. In agree-
ment with this notion, microinjection of 
worm, fly, or human VAP MSP domains 
into the MSP-deficient gonad of C. 
elegans rescues the gonadal pheno-133, June 13, 2008 ©2008 Elsevier Inc. 949
type (Tsuda et al., 2008). VAP carrying 
the P56S mutation mimics the wild-
type protein in this assay, demonstrat-
ing that the mutant protein still retains 
functional signaling properties. This 
further suggests that the defects of the 
mutant protein are primarily a result of 
aberrant trafficking and a propensity to 
develop aggregates, not loss of its nor-
mal activities.
MSP domains bind to multiple recep-
tors including the C. elegans VAB-1 
Eph-related receptor protein tyrosine 
kinase (Calò et al., 2006). Tsuda et al. 
demonstrate that dVAP also modulates 
Eph receptor signaling pathways. Both 
Drosophila and C. elegans mutants lack-
ing VAP have phenotypes that overlap 
with those observed in Eph receptor 
mutants. In addition, loss of function of 
the Drosophila Eph receptor suppresses 
the muscle phenotypes induced by over-
expression of wild-type dVAP. Lastly, the 
C. elegans and mammalian VAP MSP 
domains bind directly to their respective 
Eph receptor ectodomains. The similarity 
between the phenotypes of VAP mutants 
and Eph receptor mutants suggests that 
binding of VAP MSP domains to this 
receptor activates signaling. Whether 
this ligand/receptor interaction leads to 
positive or negative regulation of down-
stream signaling cascades, the nature of 
these pathways, and whether they are 
phosphorylation dependent or phospho-
rylation independent remain open ques-
tions. However, the abundance of differ-
ent Eph receptors, many of which are 
expressed in the neuromuscular junc-
tion and brain, and the observation that 
the VAP MSP domain can be cleaved 
and secreted (rather than remaining 
membrane-bound like the ephrins) raise 
the possibility that VAPs may act in an 
autocrine or paracrine fashion, or both. 
In addition, VAP/Eph receptor binding 
could have very different effects on sig-
nal transduction based on the type of 
receptors expressed by individual cells. 
For example, binding to Eph receptors 
expressed by neurons could stabilize 
synapses—indeed ephrins and Eph 
receptors have been shown to impact 
NMDA glutamate receptor clustering 
and synaptic plasticity (Calò et al., 2006). 
Thus, it is possible that defective VAPB-
P56S signaling in ALS patients with the 
rare familial form of the disease and car-
rying this particular mutation might alter 
the susceptibility of motor neurons to 
proposed pathogenic mechanisms such 
as glutamate excitotoxicity. Moreover, 
data from the Tsuda et al. study suggest 
that disrupted secretion by motor neu-
rons of the VAPB MSP domain caused 
by the P56S mutation could mediate 
the effects on glia, endothelia, or mus-
cle cells described in ALS patients and 
in transgenic animal models express-
ing mutant SOD1 (Pasinelli and Brown, 
2006).
The relevance of this VAP signaling 
activity to human ALS will rest on defin-
ing the cellular activities of VAPB that 
are critical for the normal function and 
maintenance of motor neurons, and 
how each is affected by the P56S muta-
tion. This provocative new report by 
Figure 1. Effects of the ALS-Associated VAP Mutation
VAP (VAMP-associated membrane protein) contains an N-terminal MSP (major sperm protein) domain, 
a central coiled-coil domain, and a C-terminal transmembrane region. It exists as an endoplasmic re-
ticulum (ER)-localized type II membrane protein and modulates diverse pathways including ER homeo-
stasis and ceramide and sphingolipid metabolism. In addition, VAP is cleaved by an unknown protease, 
releasing MSP domain-containing fragments that are secreted. Extracellular cleavage is shown here; 
however, the cellular location of this event remains to be determined; the resulting VAP fragments bind 
to Eph receptors (EphRs) although again the location is unknown (Tsuda et al. suggest from their fly 
model that the location of VAP fragment binding to EphRs could be in the Drosophila flight muscles). 
VAP fragments could also act in an autocrine way to modulate neuronal activity, for example, via gluta-
mate receptors (GluRs). The proline 56 to serine (P56S) mutation (P58S in Drosophila) in VAPB has been 
observed in a subset of ALS patients with the rare familial form of the disease. This mutation results in 
aggregation of the mutant (red) and wild-type (yellow) VAP protein in the ER, upregulation of the unfolded 
protein response (UPR), and loss of VAP function including Eph receptor signaling and probably other 
ER-associated activities of VAP.950 Cell 133, June 13, 2008 ©2008 Elsevier Inc.
Tsuda et al. raises at least three possible 
mechanisms by which VAPB could be 
involved in motor neuron disease (Figure 
1). First, prolonged ER stress induced 
by the dominant-negative aggregation 
of mutant and wild-type VAPB proteins 
might directly mediate cellular toxicity. 
Second, the loss of VAPB’s ability to 
anchor FFAT-motif-containing enzymes 
required for lipid metabolism in the ER 
might predispose motor neurons to cell 
death (Hanada et al., 2007). Finally, a 
reduction in the newly described VAP 
MSP signaling activity through Eph 
receptors (and possibly other receptors) 
could result in a non-cell-autonomous 
activation of motor neuron death. Of 
course, aspects of each scenario may 
occur simultaneously. It is interesting to Secretory cargo made in the endoplas-
mic reticulum transits through the Golgi 
apparatus, where various posttransla-
tional modifications occur, prior to sorting 
into different tubulovesicular carriers for 
transport to the surface of the cell (Far-
quhar and Palade, 1981). In one model 
for Golgi function called the vesicular 
transport model, each stack is static with 
its own defined structure and enzymes 
(Figure 1). Cargo is delivered to the stack 
by fusion of a membrane-bound vesi-
cle. Next, the cargo is sorted out of the 
stack into a vesicle that in turn fuses to 
the subsequent stack. Thus, cargo that 
enters on one face of the Golgi is trans-
ported in a series of vesicular transport 
steps to the other end. A second model, 
called the maturation model, proposes 
Golgi Governan
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It is a subject of intense debate w
nous stacks of the Golgi or whe
Patterson et al. (2008) present evi
structure and proteins rapidly eqspeculate that loss of some or all of these 
activities might account for the variability 
in human disease phenotypes observed 
with VAPB-P56S mutations.
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model with the observations that some 
cargo molecules that are too large to fit 
into vesicles, such as collagen precur-
sors or cell wall fragments in algae called 
scales, still make their way through the 
Golgi (reviewed in Pelham and Rothman, 
2000). Likewise, the observations that 
vesicles at the rims of the Golgi contain 
only cargo molecules with no enzymes 
(Orci et al., 2000) are difficult to reconcile 
with the maturation model.
A seminal review by Pelham and Roth-
man (2000) proposed a potential resolution 
of two models for the movement of cargo 
within the Golgi. They put forward the 
notion that vesicles carrying small cargo 
“percolate” in both directions through the 
stack with rapid transport rates, whereas 
larger cargo move via slow cisternal move-
ay
y vesicles through the membra-
 the cargo along. In this issue, 
e Golgi stacks are a continuous 
